SSelectStock
Sign in

ANTHEMAnthem Biosciences Limited

Pharma · Biotechnology · NSE · as of 2026-07-20 (delayed ~30 min in market hours)

791.55
1.87%
76Strong

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)43,645.20
P/E74.71
P/B14.35
PEG0.59
ROE %21.71
ROCE %22.80
Debt / Equity0.02
EPS10.40
Revenue Growth %26.00
Profit Growth %125.80
Dividend Yield %0.26
Promoter Holding %84.18
FII Holding %10.76
DII Holding %
Beta0.71

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

Bollinger SqueezeLONG77%791.55764.40845.842.00
BUYConviction 86%

Why buy

  • Revenue growth: 26.0% YoY
  • Profit growth: 125.8% YoY
  • ROE: 21.7%
  • RSI: 62
  • MACD: fresh bullish crossover
  • Price vs EMA21: above
  • Bollinger Squeeze signal (setup quality 77%)

Bull case

  • Revenue growth: 26.0% YoY
  • Profit growth: 125.8% YoY
  • ROE: 21.7%
  • RSI: 62

Bear case

  • Valuation vs sector: P/E 74.7 vs sector 38.6
  • Dividend yield: 0.26%
  • Supertrend: bearish
  • Trend strength (ADX): 15

Key risks

  • Valuation vs sector: P/E 74.7 vs sector 38.6
  • Dividend yield: 0.26%

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹791.55
Stop Loss
₹744.51
risk 5.9%
Target 1 (1.5R)
₹862.11
+8.9%
Target 2 (3R)
₹932.67
+17.8%
Support (20d)
₹742.50
Resistance (52w)
₹871.23
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹47.04/share
ATR (volatility)
₹18.82
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹18.82). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental
85
Technical
75
Momentum
70
Risk (safety)
72

Peers — Pharma

PGHL 0.78%
84
AJANTPHARM 1.45%
82
HESTERBIO 3.09%
81
LUPIN 1.44%
80
SUNPHARMA 1.23%
80
CORONA 0.78%
79

About

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India.